About Us

As a leading provider of innovative technologies for the treatment of Atrial Fibrillation (Afib) and related conditions, electrophysiologists and cardiothoracic surgeons around the globe count on AtriCure to deliver best-in-class solutions that can treat even the most complex cases. Our Isolator® Synergy™ Ablation System is the first and only medical device approved by the FDA for the treatment of long standing persistent Afib, our AtriClip Left Atrial Appendage (LAA) Exclusion System products are the most widely used LAA management devices worldwide, and we are expanding into pain management therapies. We invest in innovation, clinical science, and education to focus on improving lives for our patients worldwide.


We are passionately focused on reducing the global Afib epidemic and healing the lives of those affected.


We work to heal the lives of Patients, empower our People, and collaborate with our Partners to reduce the burden of Afib worldwide.


Our first responsibility is to put patients first. We lead rigorous clinical science to determine the safest, most effective approaches and treatments. Our commitment to education generates consistent, predictable practices and standards of care. We undertake relentless innovation to reveal new ideas that improve the experience of providers and supports the care they deliver to each patient.


Our people act with unwavering integrity and transparency in all we do. While honoring the dignity of each person, we foster collaboration to achieve excellence across all areas. We sustain a humble culture of gratitude for each other and the good that we can bring to the world.


We are committed to delivering the highest quality and most efficient solutions to benefit our partners, including care providers, customers, and shareholders. We strive to understand their needs and to offer the products, services, and business value that meet those needs.

Key Facts

  • Served over 350,000 patients with ablation
  • Over 2,500 healthcare professionals trained
  • Products sold in over 50 countries
  • Over 200,000 AtriClip devices sold worldwide
  • 138 issued patents (USA)
  • More than 700 employees worldwide
  • Headquartered near Cincinnati, Ohio
  • Developed first and only device approved by FDA for surgical treatment of persistent and longstanding persistent Afib

Our Quality Policy

AtriCure’s quality policy represents its commitment to complying with quality standards and regulations.

Like what you hear?

See if an open job opportunity is a fit for me. View openings.